CA2503303A1 - Flavivirus fusion inhibitors - Google Patents

Flavivirus fusion inhibitors Download PDF

Info

Publication number
CA2503303A1
CA2503303A1 CA 2503303 CA2503303A CA2503303A1 CA 2503303 A1 CA2503303 A1 CA 2503303A1 CA 2503303 CA2503303 CA 2503303 CA 2503303 A CA2503303 A CA 2503303A CA 2503303 A1 CA2503303 A1 CA 2503303A1
Authority
CA
Canada
Prior art keywords
group
xaa
seq
peptide
terminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2503303
Other languages
English (en)
French (fr)
Inventor
Robert F. Garry
Srikanta Dash
David H. Coy
Jane A. Mckeating
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Tulane University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2503303A1 publication Critical patent/CA2503303A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24311Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA 2503303 2002-11-08 2003-11-07 Flavivirus fusion inhibitors Abandoned CA2503303A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42474602P 2002-11-08 2002-11-08
US60/424,746 2002-11-08
PCT/US2003/035666 WO2004044220A2 (en) 2002-11-08 2003-11-07 Flaviviris fusion inhibitors

Publications (1)

Publication Number Publication Date
CA2503303A1 true CA2503303A1 (en) 2004-05-27

Family

ID=32312869

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2503303 Abandoned CA2503303A1 (en) 2002-11-08 2003-11-07 Flavivirus fusion inhibitors

Country Status (8)

Country Link
US (3) US7416733B2 (enExample)
EP (3) EP1558276B1 (enExample)
JP (2) JP5250179B2 (enExample)
AU (1) AU2003295427A1 (enExample)
CA (1) CA2503303A1 (enExample)
DK (1) DK1558276T3 (enExample)
ES (1) ES2390874T3 (enExample)
WO (1) WO2004044220A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002501A2 (en) * 2003-04-22 2005-01-13 Children's Medical Center Corporation Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
EP1797112B1 (en) 2004-09-29 2010-07-21 The Administrators of the Tulane Educational Fund Inhibitors of hepatitits c virus
US7592315B2 (en) 2004-11-02 2009-09-22 Schering Corporation Peptide viral entry inhibitors
AU2006311938A1 (en) * 2005-11-02 2007-05-18 Ambrx, Inc. Biosynthetic polypeptide fusion inhibitors
CA2643819C (en) * 2006-02-27 2018-11-27 Ilya Frolov Pseudoinfectious flavivirus and uses thereof
US7943148B1 (en) * 2007-04-04 2011-05-17 The United States Of America As Represented By The Secretary Of The Army Amino acid sites in Flavivirus E proteins useful for development of diagnostics and vaccines
EP2202298A1 (en) * 2008-12-23 2010-06-30 Stichting Dienst Landbouwkundig Onderzoek Recombinant classical swine fever virus (CSFV) comprising a modified E2 protein and methods for generating said recombinant CSFV
US20130203655A1 (en) * 2010-02-12 2013-08-08 Margaret Kielian Methods for preventing or treating viral infection
WO2016037985A1 (en) * 2014-09-08 2016-03-17 Ruprecht-Karls-Universität Heidelberg Construct for the delivery of a molecule into the cytoplasm of a cell
KR101886286B1 (ko) * 2016-11-21 2018-08-10 주식회사 옵티팜 돼지파보바이러스 및 돼지열병바이러스에 대한 동시 항원성 복합 항원 단백질의 제조 방법
CN111454989B (zh) * 2020-04-04 2022-03-08 中国农业科学院兰州兽医研究所 一种嵌合型基因i型乙型脑炎病毒病毒样颗粒疫苗及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0768267B2 (ja) * 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
DE4041304A1 (de) * 1990-12-21 1992-06-25 Mikrogen Molekularbiol Entw Von strukturproteinen des hepatitis c-virus abgeleitete polypeptide, testkits, die diese polypeptide enthalten und impfstoffe gegen infektionen von hepatitis c-viren
JPH06205672A (ja) * 1992-03-19 1994-07-26 Nippon Zeon Co Ltd 日本脳炎ウイルス及びb型肝炎ウイルスの表面抗原タンパク質の抗原部位を持つキメラタンパク質の製造法、およびそれに用いる組み換えバキュロウイルス
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5610009A (en) 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
US6180109B1 (en) * 1994-06-17 2001-01-30 Instituut Voor Dierhouderij En Diergezondheid Nucleotide and polypeptide sequences of pestivirus strains
US6117640A (en) * 1995-05-02 2000-09-12 The United States Of America As Represented By The Secretary Of The Army Recombinant vaccine made in E. coli against dengue virus
US6037348A (en) * 1996-02-09 2000-03-14 Eli Lilly And Company Inhibition of viral replication
EP1028972B1 (en) * 1997-11-06 2010-09-29 Innogenetics N.V. Multi-mer peptides derived from hepatitis c virus envelope proteins for diagnostic use and vaccination purposes
CA2330086A1 (en) * 1998-04-24 1999-11-04 Washington University Chimeras of hepatitis c virus and bovine viral diarrhea virus
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
EP0982402A1 (en) * 1998-08-14 2000-03-01 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Pestivirus vaccination
AU5460900A (en) * 1999-06-04 2000-12-28 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious cdna clone of gb virus b and uses thereof
US6750008B1 (en) 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
AU785216B2 (en) * 1999-09-17 2006-11-09 Keio University Humanin, a polypetide suppressing neuronal death
GB2372991B (en) * 2001-03-09 2004-11-17 Fiocruz Fundacao Oswaldo Cruz Flavivirus expression vector

Also Published As

Publication number Publication date
US7854937B2 (en) 2010-12-21
AU2003295427A8 (en) 2004-06-03
US7416733B2 (en) 2008-08-26
JP5250179B2 (ja) 2013-07-31
AU2003295427A1 (en) 2004-06-03
EP2360168A1 (en) 2011-08-24
EP1558276A2 (en) 2005-08-03
DK1558276T3 (da) 2012-10-22
ES2390874T3 (es) 2012-11-19
US8153360B2 (en) 2012-04-10
EP1558276A4 (en) 2006-09-13
US20110130328A1 (en) 2011-06-02
EP2338894A1 (en) 2011-06-29
WO2004044220A3 (en) 2005-05-06
JP2010280682A (ja) 2010-12-16
JP2006507328A (ja) 2006-03-02
EP1558276B1 (en) 2012-07-25
US20050271677A1 (en) 2005-12-08
WO2004044220A2 (en) 2004-05-27
US20090209464A1 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
US8153360B2 (en) Flavivirus fusion inhibitors
Garry et al. Proteomics computational analyses suggest that hepatitis C virus E1 and pestivirus E2 envelope glycoproteins are truncated class II fusion proteins
Rice et al. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution
Santolini et al. Biosynthesis and biochemical properties of the hepatitis C virus core protein
AU717542B2 (en) Synthetic hepatitis C genes
ITRM940092A1 (it) Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
Trent et al. Partial nucleotide sequence of St. Louis encephalitis virus RNA: structural proteins, NS1, ns2a, and ns2b
ES2244050T3 (es) Vacunas quimericas de flavivirus.
US20080241156A1 (en) Inhibitors of hepatitis C virus
EP0644894B1 (en) Peptide for stimulation of cytotoxic t lymphocytes specific for hepatitis c virus
ES2235310T3 (es) Epitopos de la proteina pre-m/m del virus del dengue, peptidos sinteticos.
CA2090335A1 (en) Non-a, non-b hepatitis virus antigen, diagnostic methods and vaccines
HK1168359A (en) Flavivirus fusion inhibitors
HK1156632A (en) Flavivirus fusion inhibitors
AU2012200012B2 (en) Inhibitors of hepatitis C virus
US20050074752A1 (en) Synthetic hepatitis C genes
MXPA99006629A (en) Epitopes of the protein pre-m/m of the dengue virus, synthetic peptides

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20151109